Allelix Biopharmaceuticals Inc. said Wednesday that it has completedPhase I clinical trials with ALX40-4C, a treatment that inhibits HIVreplication by interfering with the viral process of transactivation.In the trial, groups of asymptomatic HIV-positive patients were givendifferent doses of the drug, which was well-tolerated, said GrahamStrachan, president and chief executive officer of the Mississauga,Ontario, company.Allelix plans to file an investigational new drug application with theCanadian Health Protection Branch in the third quarter of this year fora Phase I/II clinical trial to determine the safety and efficacy ofALX40-4C in people with HIV.

(c) 1997 American Health Consultants. All rights reserved.